8VC’s Investment in Unlearn.AI

Imagine you have an incurable disease — maybe Alzheimer’s or multiple sclerosis. Though you might be willing to take a chance on science, you would nonetheless face a difficult decision in choosing whether to volunteer for a clinical trial. While you could potentially receive a better treatment, it’s equally likely that you would instead receive a placebo as part of the control arm of the study, used to verify the efficacy of the experimental drug. Despite bravely seeking to improve your life, you might end up as just a baseline comparator. That system doesn’t seem right.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.